FIND supports Global Fund replenishment

FIND supports Global Fund replenishment

With their Seventh Replenishment now underway, FIND expresses solidarity and support to our partner the Global Fund, as they aim to raise US$18 billion. The money is needed to get the world back on track towards ending HIV, TB and malaria, to build resilient and sustainable systems for health and strengthen pandemic preparedness, and to make the world more equitable and safer from future threats.

The robust targets set by Global Fund to get back on track to deliver the Sustainable Development Goals for the three diseases by 2030 are achievable. The COVID-19 response proved that political and financial support does unlock transformative progress in global health. FIND stands ready to build on our ACT-Accelerator partnership with Global Fund by helping to ensure that the new tests catalysed through COVID-19 investments can now be capitalized on for HIV, TB, and malaria – and further increase value for money across health systems.

Global Fund and FIND jointly can create significant value for money:

for health systems strengthening, through

  • Scale-up of next-generation platform technologies, notably including point-of-care molecular tests that can diagnose multiple diseases, including TB and other respiratory illnesses, and to manage HIV, using the same instrument. This will support the Global Fund’s focus on transforming disease-centred care to patient-centred care, allowing patients to access all services closer to home, and helping them start appropriate treatment faster
  • Implementation of diagnostic network optimization analyses and market shaping activities to ensure that the maximum number of people can be reached while improving returns on Global Fund investments

in HIV, through

  • Development, evaluation and roll out of rapid tests to enable so-called “triple elimination” of mother-to-child transmission of HIV, syphilis, and hepatitis B
  • Development, evaluation and roll out of new viral load rapid tests urgently needed for test-and-treat approaches in primary care

in TB, through

  • Development, evaluation and roll out of next-generation TB detection tests using swabs or urine samples suitable for primary care; implementing diagnostics that can provide on-the-spot results could increase the total number of people successfully treated for TB by 17%, which means saving as many as 750,000 additional lives between 2024 and 2026
  • Evaluation and roll-out of specific skin tests that can identify those with TB infection that can be treated to prevent future illness and transmission
  • Development and evaluation of novel tools and bespoke strategies to support TB detection in children and people living with HIV, who often cannot produce the sputum required for traditional tests
  • Boosting in-country capacity for the adoption of targeted next-generation sequencing tools that will enable affordable, scalable and rapid drug-susceptibility testing and improve disease surveillance

in malaria, through

  • Evaluation and roll out of highly sensitive rapid tests that can boost malaria detection to include low parasitaemia and asymptomatic infections, including in pregnant women whose diagnoses are often missed by existing tests
  • Development, evaluation and roll out of rapid tests that can detect different malaria species, notably Plasmodium vivax, and which use diverse biomarkers and sample types
  • Building on experience in the COVID-19 response, use the Global Fund’s market shaping potential to significantly reduce the cost of tests

Together, we can make sure everyone who needs a test can get one – to make HIV, TB and malaria elimination a reality.